{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:25:44Z","timestamp":1793291144614,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacc.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:06:41Z","timestamp":1753711601000},"page":"354-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases"],"prefix":"10.1016","volume":"86","author":[{"given":"Francesco","family":"Fioretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Testani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clarissa","family":"Tio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.06.012_bib1","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.06.012_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.jacc.2025.06.012_bib3","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib4","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib5","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1210\/mend-5-10-1513","article-title":"The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex","volume":"5","author":"Curnow","year":"1991","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0303-7207(96)03853-1","article-title":"Differential regulation of 11 beta-hydroxylase and aldosterone synthase in human adrenocortical H295R cells","volume":"121","author":"Denner","year":"1996","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/FJC.0000000000000999","article-title":"The angiotensin II type 1 (AT1) receptor and cardiac hypertrophy: did we have it wrong all along?","volume":"77","author":"Zouein","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"van de Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.06.012_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.tvir.2010.02.006","article-title":"Adrenal vein sampling","volume":"13","author":"Kahn","year":"2010","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.vh.2018.10.001","article-title":"Paracrine regulation of aldosterone secretion in physiological and pathophysiological conditions","volume":"109","author":"Lefebvre","year":"2019","journal-title":"Vitam Horm"},{"key":"10.1016\/j.jacc.2025.06.012_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2025.06.012_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mce.2009.01.019","article-title":"The adipose renin-angiotensin system: role in cardiovascular disease","volume":"302","author":"Thatcher","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccl.2010.04.001","article-title":"The role of aldosteronism in causing obesity-related cardiovascular risk","volume":"28","author":"Calhoun","year":"2010","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacc.2025.06.012_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1081\/ERC-200044122","article-title":"Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells","volume":"30","author":"Ehrhart-Bornstein","year":"2004","journal-title":"Endocr Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib23","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.06.012_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/157016111794519318","article-title":"Pleiotropic effects of ARB in metabolic syndrome","volume":"9","author":"Yamada","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib26","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/HYPERTENSIONAHA.108.128512","article-title":"Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1","volume":"53","author":"Staermose","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mce.2014.08.003","article-title":"Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-\u03baB signal pathway in rat vascular smooth muscle cells","volume":"395","author":"Zhang","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/hr.2011.16","article-title":"Aldosterone\/NaCl-induced renal and cardiac fibrosis is modulated by TGF-\u03b2 responsiveness of T cells","volume":"34","author":"Schreier","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib29","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","article-title":"Cardiovascular complications in patients with primary aldosteronism","volume":"33","author":"Nishimura","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2025.06.012_bib31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3803\/EnM.2018.33.4.429","article-title":"Primary aldosteronism and cerebrovascular diseases","volume":"33","author":"Chen","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jacc.2025.06.012_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/HJH.0000000000001251","article-title":"Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism","volume":"35","author":"Murata","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2337\/dc18-1293","article-title":"High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan","volume":"42","author":"Akehi","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.06.012_bib36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-15-0450","article-title":"Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry","volume":"173","author":"Hanslik","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.06.012_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.06.012_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.06.012_bib41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.06.012_bib42","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.06.012_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib44","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"G\u00fcder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.012_bib45","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.012_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2459\/JCM.0b013e328364129c","article-title":"Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up","volume":"15","author":"Mignano","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jacc.2025.06.012_bib47","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.012_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11427-021-1945-6","article-title":"Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction","volume":"65","author":"Ke","year":"2022","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jacc.2025.06.012_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11906-020-1028-6","article-title":"Recent research advances in renin-angiotensin-aldosterone system receptors","volume":"22","author":"Azushima","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jacc.2025.06.012_bib50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","article-title":"Nongenomic actions of aldosterone: from receptors and signals to membrane targets","volume":"350","author":"Dooley","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2091-12-54","article-title":"Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3","volume":"12","author":"Gordon","year":"2011","journal-title":"BMC Biochem"},{"key":"10.1016\/j.jacc.2025.06.012_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ajh.2011.197","article-title":"Activation of the mineralocorticoid receptor increases striatin levels","volume":"25","author":"Pojoga","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/en.2009-0514","article-title":"Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II","volume":"151","author":"Pojoga","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2025.06.012_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.vh.2018.12.001","article-title":"Nongenomic effects of aldosterone","volume":"109","author":"Mihailidou","year":"2019","journal-title":"Vitam Horm"},{"key":"10.1016\/j.jacc.2025.06.012_bib55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.HYP.0000205225.88721.2c","article-title":"Nongenomic renal effects of aldosterone: dependency on NO and genomic actions","volume":"47","author":"Chun","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.physiol.59.1.365","article-title":"Specific, nongenomic actions of steroid hormones","volume":"59","author":"Wehling","year":"1997","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib57","doi-asserted-by":"crossref","first-page":"C532","DOI":"10.1152\/ajpcell.00203.2012","article-title":"Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation","volume":"304","author":"Gros","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib59","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/ME.2014-1410","article-title":"Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury","volume":"29","author":"Ashton","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib60","first-page":"4296","article-title":"Nongenomic effects of aldosterone on phosphocreatine levels in human calf muscle during recovery from exercise","volume":"81","author":"Zange","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.06.012_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0950687","article-title":"Aldosterone blunts the baroreflex response in man","volume":"95","author":"Yee","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2025.06.012_bib62","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/0024-3205(82)90441-6","article-title":"Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle","volume":"30","author":"Weber","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.jacc.2025.06.012_bib63","doi-asserted-by":"crossref","first-page":"45892","DOI":"10.1074\/jbc.M208851200","article-title":"Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling","volume":"277","author":"Krug","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib64","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2003.10.018","article-title":"A quick glance at rapid aldosterone action","volume":"217","author":"L\u00f6sel","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib66","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41371-020-00426-y","article-title":"Left ventricular remodeling and dysfunction in primary aldosteronism","volume":"35","author":"Tsai","year":"2021","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib68","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-19-0047","article-title":"Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism","volume":"181","author":"Kawashima","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib70","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib72","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2025.06.012_bib73","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib74","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.06.012_bib75","first-page":"1801","article-title":"[Studies on organ- and subcellular distribution of 3 H-spironolactone in animals]","volume":"22","author":"Platt","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jacc.2025.06.012_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib77","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib78","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib79","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacc.2025.06.012_bib81","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/jcm12123992","article-title":"Finerenone: questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist","volume":"12","author":"Di Lullo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib82","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib83","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib84","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacc.2025.06.012_bib85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib86","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib88","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.012_bib90","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.012_bib91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib92","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2025.06.012_bib93","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.06.012_bib94","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacc.2025.06.012_bib95","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2025.06.012_bib96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.012_bib98","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.06.012_bib99","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2025.06.012_bib100","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.06.012_bib101","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.06.012_bib102","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.06.012_bib104","series-title":"Medical Pharmacology and Therapeutics","first-page":"3","article-title":"1 - principles of pharmacology and mechanisms of drug action","author":"Waller","year":"2018"},{"key":"10.1016\/j.jacc.2025.06.012_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.06.012_bib106","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","article-title":"Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator","volume":"84","author":"Erlandsson","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib107","doi-asserted-by":"crossref","DOI":"10.1177\/1470320319827449","article-title":"The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone","volume":"20","author":"Bamberg","year":"2019","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jacc.2025.06.012_bib108","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.122.001240","article-title":"Mass balance and absorption, distribution, metabolism, and excretion properties of balcinrenone following oral administration in combination with intravenous microtracer in healthy subjects","volume":"51","author":"Lindmark","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2025.06.012_bib109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","article-title":"Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study","volume":"13","author":"Whittaker","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacc.2025.06.012_bib110","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/cts.13377","article-title":"Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: a randomized trial","volume":"15","author":"Squire","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.jacc.2025.06.012_bib111","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ejhf.3387","article-title":"Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?","volume":"27","author":"Beldhuis","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.012_bib112","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.012_bib115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","article-title":"Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients","volume":"27","author":"Ramsay","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.06.012_bib116","doi-asserted-by":"crossref","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","article-title":"Characterization of 2 genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)","volume":"264","author":"Mornet","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam Horm"},{"key":"10.1016\/j.jacc.2025.06.012_bib118","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib119","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib120","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.06.012_bib121","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase 3 study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.06.012_bib122","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacc.2025.06.012_bib123","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib124","article-title":"Efficacy and Safety of Baxdrostat in Patients With Uncontrolled Hypertension \u2013 HALO","author":"Eagle","year":"2023","journal-title":"American College of Cardiology"},{"key":"10.1016\/j.jacc.2025.06.012_bib127","series-title":"Mineralys Therapeutics","article-title":"Mineralys therapeutics completes enrollment ahead of schedule in Launch-HTN, the second pivotal trial of Lorundrostat for the treatment of hypertension","year":"2024"},{"key":"10.1016\/j.jacc.2025.06.012_bib128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.06.012_bib131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1056\/NEJMe2213559","article-title":"Aldosterone and treatment-resistant hypertension","volume":"388","author":"Leopold","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib132","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/bph.15719","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","volume":"179","author":"Clarisse","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2025.06.012_bib133","series-title":"Endotext. MDText.com","article-title":"Aldosterone deficiency and resistance","author":"Arai","year":"2000"},{"key":"10.1016\/j.jacc.2025.06.012_bib134","first-page":"21","article-title":"Persistent hypoaldosteronism post-adrenalectomy for primary aldosteronism - a role for pre-operative spironolactone?","volume":"2021","author":"Angus","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.jacc.2025.06.012_bib135","series-title":"Hypoaldosteronism","author":"Rajkumar","year":"2024"},{"key":"10.1016\/j.jacc.2025.06.012_bib136","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.surg.2017.07.034","article-title":"Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism","volume":"163","author":"Shariq","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.jacc.2025.06.012_bib137","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.06.012_bib138","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib139","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ahj.2014.12.016","volume":"169","author":"Schroten","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-4731(83)80046-6","article-title":"Aldosterone metabolites and possible aldosterone precursors in hypertension","volume":"19","author":"Vecsei","year":"1983","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.jacc.2025.06.012_bib141","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/clinchem\/37.10.1843","article-title":"Steroid characteristics of mineralocorticoid adrenocortical hypertension","volume":"37","author":"Biglieri","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib142","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib143","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib144","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib146","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/jcem-40-2-205","article-title":"Integrated concentration of plasma aldosterone in normal subjects: correlation with cortisol","volume":"40","author":"Kowarski","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jacc.2025.06.012_bib147","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2025.06.012_bib148","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0960-0760(92)90220-D","article-title":"Tissue localization of 11 beta-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor","volume":"41","author":"Whorwood","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jacc.2025.06.012_bib149","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jacc.2025.06.012_bib150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib151","doi-asserted-by":"crossref","first-page":"27634","DOI":"10.1074\/jbc.M003170200","article-title":"The Rac1\/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins","volume":"275","author":"Uddin","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.06.012_bib152","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.RES.84.4.458","article-title":"Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes","volume":"84","author":"Aikawa","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib153","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.06.012_bib154","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/hr.2016.137","article-title":"Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension","volume":"40","author":"Shibata","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib156","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib157","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacc.2025.06.012_bib158","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/ajh\/hps080","article-title":"Age-related changes in 11\u03b2-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects","volume":"26","author":"Campino","year":"2013","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2025.06.012_bib159","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.06.012_bib160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.06.012_bib161","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.06.012_bib162","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.06.012_bib163","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.06.012_bib168","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.06.012_bib169","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.06.012_bib170","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972506807X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972506807X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:28:17Z","timestamp":1787646497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972506807X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":158,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S073510972506807X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.06.012","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}